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AbstrAct
Dent’s disease type 1 is an X-linked tu-
bular disease caused by mutations in the 
renal chloride channel CLCN-5, and it 
is characterized by low molecular weight 
proteinuria, hypercalciuria, nephrocal-
cinosis, and renal failure. Several cases 
have been described in which the only 
presenting symptoms were asymptoma-
tic proteinuria, and focal segmental or 
global glomerulosclerosis. The renal fai-
lure in these patients may be caused by 
hypercalciuria and persistent proteinuria. 
Therefore, angiotensin converse enzyme 
inhibitor and thiazides could be useful. 
Our aim is to report the effects of these 
drugs in two novel mutations patients wi-
th Dent’s disease type 1. In this report, no 
significant correlations between dosage of 
hydrochlorothiazide and calciuria and no 
significant correlations between proteinu-
ria and dosage of enalapril were detected. 
This is important since these are polyuric 
patients and these drugs could be dange-
rous to their renal function.
Keywords: Enalapril. Proteinuria. 
Hypercalciuria. Hydrochlorothiazide. 
Dent Disease.
resumo
A doença de Dent é uma tubulopatia li-
gada ao X causada por mutações no gene 
que codifica o canal de cloro CLCN-5 e 
é caracterizada por proteinúria de baixo 
peso molecular, hipercalciúria, nefrocal-
cinose e insuficiência renal. Vários ca-
sos têm sido descritos, nos quais o único 
sintoma na apresentação foi proteinúria 
assintomática e glomerulosclerose global 
ou segmentar. A insuficiência renal nesses 
pacientes pode ser causada pela hipercal-
ciúria e proteinúria persistente. Portanto, 
o inibidor da enzima de conversão da an-
giotensina e os tiazídicos poderiam ser 
úteis. O objetivo desta pesquisa é relatar 
os efeitos destas drogas em dois pacientes 
com doença de Dent tipo 1 com mutações 
novas. Neste relato não foram observa-
das correlações significativas entre dose 
de hidroclorotiazida e calciúria e entre 
enalapril e proteinúria. Este achado é im-
portante, pois, sendo pacientes poliúricos, 
o uso destas drogas poderia prejudicar a 
função renal 
Palavras-chave: Enalapril. Proteinúria. 
Hipercalciúria. Hidroclorotiazida. Doença 
de Dent.
Uso a longo prazo de enalapril e hidroclorotiazida em dois 
pacientes com novas mutações com doença de Dent tipo 1
The long-term use of enalapril and hydrochlorothiazide in two 
novel mutations patients with Dent’s disease type 1
IntroductIon
Dent’s disease type 1 is an X-linked tubular 
disease caused by mutations in the CLCN5 
gene that encodes the electrogenic chlori-
de/proton exchanger ClC-5.1 This disease 
is characterized by low molecular weight 
(LMW) proteinuria, hypercalciuria, ne-
phrocalcinosis, and renal failure. Patients 
may present other features of proximal 
tubular impairment.2 The most consistent 
indication of affected males is increased 
excretion of LMW proteins.3 Females are 
considered as carriers, and they show mil-
der LMW proteinuria.4 Several cases have 
been described in which the only presen-
ting symptoms were proteinuria and focal 
segmental or global glomerulosclerosis 
(FSGS).5 The major consequence of Dent’s 
disease is a progression to end-stage renal 
disease (ESRD), but the cause is unknown. 
Although hypercalciuria cannot directly 
account for the glomerular abnormalities, 
the interstitial injury caused by renal calci-
fication may contribute to glomerular in-
jury.6 The persistent proteinuria can also 
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contribute to it. Therefore, angiotensin converting en-
zyme inhibitor and thiazides could be useful to these 
patients. Our aim is to report the effects of enalapril 
and hydrochlorothiazide (HCTZ) in two novel muta-
tions in Dent’s disease type 1 Brazilian patients. The 
molecular studies were made in Tokyo University. 
The parents signed the informed consent.
cAse 1
An 11-year-old boy was referred for evaluation and 
Table 1 presents the tests performed. He had a his-
tory of failure to thrive and nephrotic proteinuria 
since he was six years-old. The patient was treated 
with immunosuppressive drugs without response. 
Family history was negative and the parents were 
non-consanguineous. His renal biopsy showed glo-
merular sclerosis (23/84 glomerulus), segmental me-
sangial proliferation and adherence to Bowman cap-
sule, mild insterstitial fibrosis, and tubular atrophy. 
Immunofluorescence showed IgM. The patient had 
nephrotic proteinuria, hypercalciuria, without hyper-
cholesterolemia and hypoalbuminemia. The renal ul-
trasound showed bilateral nephrocalcinosis grade III. 
Potassium citrate (0.5 mEq/kg/day) and enalapril were 
introduced. Dent’s disease was suspected, therefore an 
isolated urinary sample was collected to measure uri-
nary RBP (uRBP) of the patient and his mother, which 
showed first uRBP mother’s patient of 0.21 mg/L and 
the second ones was 0.63 mg/L; patient’s uRBP was 
55.9 mg/L (normal value is up to 0.4 mg/L). A mole-
cular study was carried out and revealed a novel mis-
sense G329D (GGT to GAT) mutation in Exon 8 of 
the CLCN5. The mother was a carrier and the father 
had no mutations (Figure 1 – Case A). The patient 
was treated with enalapril (0.18 ± 0.06 mg/kg/day), 
potassium citrate, and HCTZ (0.81 ± 0.17 mg/kg/day) 
for 41 months. Figures 2 and 3 show, respectively, the 
evolution of proteinuria and creatinine clearance es-
timated by stature according to Schwartz formula7 
parameters. The patient did not tolerate (hypotension 
symptoms) higher doses of these medications. 
There were no significant correlations between 
dosage of enalapril and proteinuria (n = 12 measure-
ments, r = -0.19 and p = 0.56) or between calciuria 
and dosage of HCTZ (n = 11 measurements, r = -0.15 
and p = 0.65), with Pearson’s correlation coefficient. 
The diuresis observed was of 2.0 ± 0.9 mL/kg/hour. 
After three months without enalapril and HCTZ, 
a decrease in serum creatinine level from 1.50 to 
1.06 mg/dL was observed, and proteinuria and hyper-
calciuria were kept in the same range.
cAse 2
A four-year-old male was referred to investigate hyper-
calciuria and proteinuria. Table 1 presents the tests that 
were performed in this patient. He presented failure to 
thrive and polydipsia when he was 1 year-old. The renal 
biopsy showed calcification in interstitium. His gran-
dfather had nephrolithiasis and the parents were non-
consanguineous. This patient had a nephrotic proteinu-
ria without hypoalbuminemia or hypercholesterolemia, 
hypercalciuria and normocalcemia. Nephrocalcinosis 
grade I was detected. The uRBP mother’s patient was of 
0.9 mg/L and the patient presented uRBP of 62 mg/L. The 
molecular study showed a novel missense L278W (TTG 
to TGG) mutation in Exon 8 of the CLCN5. The mother 
was a carrier and the father had no mutations (Figure 1 
– Case B).This patient was treated with potassium ci-
trate (0.5 mEq/kg/day), HCTZ (1.90 ± 0.62 mg/kg/day) 
and enalapril (0.31 ± 0.05 mg/kg/day) for 48 months. 
Table 1 tests at fiRst attendanCe of the two dent’s disease patients with long-teRm follow-up
Test Case 1 Case 2 Normal values
Serum creatinine (mg/dL) 1.1 0.3 0.5 – 0.8
Serum urea (mg/dL) 37 30 13 – 36
Serum albumin (g/L) 5 4.5 3.8 – 5.6
ionic calcium (mmol/L) 1.25 1.31 1.12 – 1.32
Serum sodium/serum potassium (mEq/L) 141 / 4.5 142 / 4.0 135 – 147 / 3.7 – 5.0
Estimated creatinine clearance (mL/min./1.73 m2) 66.5 172 ≥ 90
Calciuria (mg/kg/day) 13.5 6.3 < 4
Proteinuria (mg/kg/day) 51 65 < 10
Total cholesterol (mg/dL) 186 147 < 170
Triglycerides (mg/dL) 36 46 < 100
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Figures 2 and 3 show, respectively, the evolution of pro-
teinuria and creatinine clearance estimated by stature 
according to Schwartz Formula.7 Although he tolerated 
higher doses of the drugs than patient 1, no significant 
correlation between proteinuria and dosage of enalapril 
(n = 12 measurements, r = 0.43 and p = 0.16) and betwe-
en calciuria and dosage of HCTZ (n = 12 measurements, 
r = -0.26 and p = 0.4) were detected (Pearson’s corre-
lation coefficient). Diuresis during this period was of 
3.2 ± 2.0 mL/kg/hour.
method of dnA sequencIng
Mutational analysis of the CLCN5 gene – leukocyte 
DNA was extracted and cDNA was purified. They 
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Figure 2. Proteinuria (mg/kg/day) in two Dent’s disease 
patients during long-term follow-up.
Figure 3. Creatinine clearance estimated by stature in 
two Dent’s disease patients during long-term follow-up.
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Figure 1. DNA sequencing chromatograms of patients and parents. A: Case 1; B: Case 2.
Figure available in color at the website: www.jbn.org.br/
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were used with CLCN5-specific primers for polyme-
rase chain reaction (PCR) amplification, using the pre-
viously described conditions.8 The DNA sequence of 
the PCR products was determined by the use of Taq 
polymerase cycle sequencing and a semi-automated 
detection system (ABI 373A sequencer; Perkin Elmer 
Japan Applied Biosystems Division, Japan).
dIscussIon
This study adopted three diagnostic criteria for 
Dent’s disease: LMW proteinuria, hypercalciuria, 
and one of the following: nephrocalcinosis, kidney 
stones, hypophosphatemia, renal failure, amino-
aciduria, rickets, or a positive family.9 However, 
Copelovitch et al. suggested that the diagnosis 
should be considered in patients with nephrotic 
proteinuria without hypoalbuminemia or edema 
and FSGS.10 This is important to avoid immuno-
suppressors as in Case 1. Dent’s disease type 1 is 
caused by mutations in the CLCN5 gene. Over one 
fourth of the mutations is missense, and they elimi-
nate or reduce ClC-5 currents.11
The current treatment is supportive. High dos-
es of thiazides can reduce calciuria and the risk of 
nephrolithiasis; however, they are poorly tolerated 
for long periods in these polyuric patients, frequently 
associated with hypovolemia and hypokalemia.12,13 
In addition, calcium concentration in the urine can 
be halved just by doubling the water intake, avoid-
ing the effects of thiazide. In addition to LMW pro-
teinuria, the glomerular component may increase 
during follow–up, and enalapril could be useful. 
We were not able to detect a significant correlation 
between the dosage of HCTZ and calciuria, as well 
as, proteinuria and enalapril, and this drug can even 
decrease the glomerular filtration rate, which was 
demonstrated by the decrease in serum creatinine af-
ter enalapril withdrawn in Case 1. Finally, the two 
missense mutations identified are predicted at the 
very important sites of ClC-5 function. Ashida and 
Ymamoto are now analyzing the sites of missense 
mutations identified so far by computational three-
dimension modeling. According to their results, the 
two mutations are located at critical sites, which are 
crucial for substrate transport or dimer formation 
(personal communication with professors Ashida 
and Ymamoto).
Since this computational modeling theory is un-
der preparation of the manuscript, the precise data 
could not be presented. Furthermore, during the anal-
ysis of more than 100 families with Dent’s disease, 
Sekine et al. have been sequencing all of the exons 
of CLCN5, and the two mutations above were not 
identified. These facts strongly indicated the two mu-
tations in this paper are exactly responsible for the 
development of Dent’s disease, and not SNPs.
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